Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.

Journal: Pain medicine (Malden, Mass.)
PMID: 26814240

Abstract

OBJECTIVES: A once-daily, extended-release hydrocodone bitartrate tablet with abuse-deterrent properties (Hysingla ER® [HYD]) is available for the treatment of chronic pain in appropriate patients. This study evaluated the intranasal abuse potential and pharmacokinetics of HYD coarse and fine particles vs hydrocodone powder or placebo.

Authors

  • Stephen C Harris
    *Purdue Pharma L.P., Stamford, Connecticut, USA; stephen.harris@pharma.com.
  • Alessandra Cipriano
    *Purdue Pharma L.P., Stamford, Connecticut, USA;
  • Salvatore V Colucci
    *Purdue Pharma L.P., Stamford, Connecticut, USA;
  • Ram P Kapil
    *Purdue Pharma L.P., Stamford, Connecticut, USA;
  • Pierre Geoffroy
    INC Research Toronto, Toronto, Ontario, Canada.
  • Talar Hopyan
    INC Research Toronto, Toronto, Ontario, Canada.
  • Naama Levy-Cooperman
    INC Research Toronto, Toronto, Ontario, Canada.

Keywords

External Resources

Popular Topics
Recent Journals